ALLO

Allogene Therapeutics Inc

$2.10
0.14 (6.31%) Today
0.02 (0.96%) After-hours
Compare ALLO
Market Cap
$766M+84.1%
Revenue (TTM)
$0
Net Income (TTM)
$-299,693,745
EPS (TTM)
-0.87
Shares Out
345.15M
Open
$2.24
Previous Close
$2.22
Day Range
$2.05 – $2.25
52-Week Range
$0.98 – $4.46
Beta
0.46
Earnings Date
Aug 11, 2026
Volume
17.95M
Avg Volume
9.21M
Analyst Rating
Buy
Exchange
NASDAQ NMS - GLOBAL MARKET

About ALLO

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

Related

News